Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 871 to 885 of 2042 results for guidelines

  1. Charging procedure: technology appraisal and highly specialised technologies evaluations

    Introduction In accordance with UK Statutory Instrument 2018 No.1322 , NICE must recover its costs for producing Technology Appraisals (TA) or Highly

  2. Technology appraisal and highly specialised technologies appeals

    Technology appraisal and Highly specialised technologies appeals

  3. Past appeals and decisions

    Down to Rejected appeals Cancelled appeals Past appeals TA ID Appraisal short title Appeal hearing date TBC Afamelanotide for erythropoietic

  4. Technology appraisal submission templates and supporting documents

    On this page, you'll find all the templates and supporting documents you need to make a technology appraisals submission. These templates have been...

  5. Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)

    Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.

  6. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

    Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.

  7. SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea (MIB190)

    NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .

  8. BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume (MIB50)

    NICE has developed a medtech innovation briefing (MIB) on the BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume

  9. Liraglutide for managing overweight and obesity (TA664)

    Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.

  10. Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)

    Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  11. Public board meeting agenda and papers: November 2020

    Agenda and papers of the NICE public board meeting on 18 November 2020

  12. Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome (MIB223)

    NICE has developed a medtech innovation briefing (MIB) on Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome .

  13. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  14. NICE health technology evaluation topic selection: the manual (PMG37)

    This is not the current manual. From 29 May 2024, health technologies are selected using the new NICE-wide topic prioritisation process (PMG46)

  15. Fruquintinib for previously treated metastatic colorectal cancer ID6274

    In development [GID-TA11280] Expected publication date: 05 March 2025